Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Two Pacritinib Formulations in Healthy Subjects
NCT02823171Phase 1Completed
- Sponsor
- CTI BioPharma Corp.
- Start
- Aug 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pacritinib in myelofibrosis (MF) (2 arms), sponsored by CTI BioPharma Corp. Primary endpoints: Apparent Total Body Clearance, Maximum Plasma Concentration and 4 more. Started Aug 2015; status: completed.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02823171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02823171.